Skip to main content
. 2022 May 16;51:21. doi: 10.1186/s40463-022-00572-y

Fig. 3.

Fig. 3

Therapy response after 4 cycles pembrolizumab/carboplatin/pemetrexed. Maximal intensity projection (MIP) of [18F]FDG PET/CT A before treatment start, B after 4 cycles immuno-chemotherapy. In A, B the area of the supraglottic laryngeal cancer is indicated by a green arrow. C Microlaryngoscopic view of the laryngeal cancer before treatment start during diagnostic panendoskopy. D Microlaryngoscopic view of the same area after 4 cycles immuno-chemotherapy during a control panendoscopy